Abstract
Calcipotriene 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) aerosol foam is a topical agent indicated for the treatment of plaque psoriasis. While topical treatments are typically reserved for milder disease, in clinical trials with Cal/BD foam, the vast majority of patients had beyond-mild psoriasis at baseline, and multiple studies (including subgroup analyses from randomized controlled trials and other small-scale studies) have demonstrated favorable outcomes with the use of Cal/BD foam in this population. The objective of this article is to review existing data on the efficacy, safety, and cost-effectiveness of Cal/BD foam used in patients with beyond-mild psoriasis, either alone as topical monotherapy or as adjunctive therapy. Practical recommendations for managing beyond-mild psoriasis with Cal/BD foam are also provided. J Drugs Dermatol. 2020;19(8): doi:10.36849/JDD.2020.5300.
MeSH terms
-
Administration, Cutaneous
-
Aerosols
-
Betamethasone / administration & dosage
-
Betamethasone / adverse effects
-
Betamethasone / analogs & derivatives*
-
Betamethasone / economics
-
Biological Products / administration & dosage*
-
Biological Products / adverse effects
-
Biological Products / economics
-
Calcitriol / administration & dosage
-
Calcitriol / adverse effects
-
Calcitriol / analogs & derivatives*
-
Calcitriol / economics
-
Cost-Benefit Analysis
-
Dermatologic Agents / administration & dosage*
-
Dermatologic Agents / adverse effects
-
Dermatologic Agents / economics
-
Drug Combinations
-
Drug Therapy, Combination / adverse effects
-
Drug Therapy, Combination / economics
-
Drug Therapy, Combination / methods
-
Humans
-
Psoriasis / diagnosis
-
Psoriasis / drug therapy*
-
Psoriasis / economics
-
Randomized Controlled Trials as Topic
-
Severity of Illness Index
-
Thalidomide / administration & dosage
-
Thalidomide / adverse effects
-
Thalidomide / analogs & derivatives
-
Thalidomide / economics
-
Treatment Outcome
Substances
-
Aerosols
-
Biological Products
-
Dermatologic Agents
-
Drug Combinations
-
calcipotriene
-
Thalidomide
-
betamethasone-17,21-dipropionate
-
Betamethasone
-
Calcitriol
-
apremilast